#curosurf
At the #jENScongress 2025 Bengt Robertson Award ceremony, we were honoured to welcome Tore Curstedt — renowned Swedish laboratory physician, together with Bengt Robertson, he developed Curosurf. The drug has saved millions of premature babies suffering from respiratory distress syndrome (RDS).
October 23, 2025 at 1:20 PM
As a curosurf scientist once told me “Simce we make it from prosciutto, babies likely taste good with Parmesan cheese”
November 17, 2024 at 6:47 PM
Recolha voluntária de lotes do medicamento Curosurf (Poractante alfa) - 120 mg-1.5 ml, suspensão para instilação endotraqueobrônquica
swki.me/eVY9OTkg

#infarmed #recolhavoluntaria #medicamentos #curosurf #poractantealfa
Recolha voluntária de lotes do medicamento Curosurf (Poractante alfa) - 120 mg-1.5 ml, suspensão para instilação endotraqueobrônquica
Infarmed
swki.me
March 31, 2026 at 9:58 AM
distribution of Curosurf in the lungs. Rheological measurements showed the viscoelastic complexity of atomized Curosurf. This preliminary study confirmed the promising potential of Curosurf atomization via the Endosurf device for the distribution of [5/6 of https://arxiv.org/abs/2506.00029v1]
June 3, 2025 at 6:14 AM
developed to provide proof of concept for regional aerosol deposition of atomized Curosurf. The atomization of Curosurf with the innovative Endosurf device did not significantly alter surface tension, but reduced vesicle size and promoted homogeneous [4/6 of https://arxiv.org/abs/2506.00029v1]
June 3, 2025 at 6:14 AM
surface tension and rheology. The size distribution of Curosurf vesicles was also investigated. An ex vivo respiratory model based on rabbit lungs breathing through an instrumented hypobaric chamber representing the thorax of a preterm infant was [3/6 of https://arxiv.org/abs/2506.00029v1]
June 3, 2025 at 6:14 AM
via the Endosurf device, a recently developed spray technology, as a promising approach for surfactant delivery in infants with RDS. A comprehensive analysis was performed to evaluate the physicochemical properties of atomized Curosurf, including its [2/6 of https://arxiv.org/abs/2506.00029v1]
June 3, 2025 at 6:14 AM
arXiv:2506.00029v1 Announce Type: new
Abstract: Administration of pulmonary surfactant is crucial for the treatment of respiratory distress syndrome (RDS) in preterm infants. The aim of this study is to evaluate the potential of Curosurf atomization [1/6 of https://arxiv.org/abs/2506.00029v1]
June 3, 2025 at 6:14 AM
Also exceptionally important for premature babies who are born before their lungs start making surfactant. One of the most common surfactant drugs (curosurf) is made from the lungs of pigs raised for artesian prosciutto
December 29, 2024 at 2:04 AM
The surfactant employed was made by this group through lipid extraction & modification of whole calf lung extract, & eventually became Survanta. (In the same era, Tore Curstedt & Bengt Robertson @karolinskainst developed the porcine product that would be Curosurf (“Curstedt-Robertson surfactant”).
November 24, 2024 at 2:28 PM
Neonatal RDS: Diabetic mother (↑insulin→↓SP-B/C) / prematurity (<34wks) → type II dysfunction → ↓surfactant (DPPC+SP-B/C) → hyaline membranes | Tachypnea+grunting + CXR: ground-glass/air bronchograms | Rx: Surfactant (Poractant🐽[Curosurf], beractant🐮)+CPAP | Prevention: Antenatal betamethasone
August 18, 2025 at 8:40 PM
The answer is B, poractant (Curosurf). The pulmonary surfactant is indicated for treatment/rescue of respiratory distress syndrome (hyaline membrane disease) in premature neonates. It is used off label as prophylaxis of RDS in infants at high risk.
November 20, 2024 at 3:19 PM
R07AA02: 4 maahantuojaa tuo Curosurf-lääkettä Suomeen. Näistä neljästä puolet on nyt ilmoittanut toimitusrajoituksista.
18/x
November 22, 2024 at 2:58 PM
R07AA02: Curosurf is imported by 4 importers to Finland. Of these four, two have now issued restrictions on deliveries.
17/x
November 22, 2024 at 2:48 PM
Use of endotracheal poractant alfa (Curosurf) did not shorten the duration of invasive mechanical ventilation for infants with bronchiolitis, a randomized phase II trial indicated. #SCCM2026
https://www.medpagetoday.com/meetingcoverage/sccm/120458
No Benefit to Surfactant in Invasive Mechanical Ventilation for Infant Bronchiolitis
Endotracheal poractant alfa joins other interventions that lack clinical benefit
www.medpagetoday.com
March 25, 2026 at 12:30 AM
The Curosurf (Poractant Alfa) market is driven by rising preterm births,NICU adoption,and respiratory disorder prevalence.Key segments include natural/synthetic types, applications, and end users.North America leads,while Asia-Pacific grows fastest.
www.thebusinessresearchcompany.com/report/curos...
Curosurf (Poractant Alfa) Market Report 2026, Share Analysis And Forecast 2035
The Curosurf (Poractant Alfa) market is witnessing steady growth over the forecast period, supported by increasing premature birth rates globally, expansion of nicu infrastructure.
www.thebusinessresearchcompany.com
March 26, 2026 at 12:06 PM